securities litigation

Law firm announces shareholder lawsuit deadlines (May 2026) against $ALIT, $GO, $GEMI over alleged materially false statements on financials, dividends, and business viability.

BFA Law investigates Willis Lease Finance board for fiduciary duty breaches over executive compensation that doubled to $14.2M, raising shareholder governance concerns.

Monteverde & Associates investigates four merger transactions including Masimo's $180/share Danaher sale, with shareholder votes scheduled for May 1, 2026.

Schall Law Firm investigates Priority Technology Holdings for potential fiduciary duty breaches, seeking NASDAQ-listed shareholders to join class action lawsuit.

Three shareholder lawsuits filed against $BRBR, $BYND, and $METC over alleged sales misstatements, asset valuations, and mine development disclosures. Lead plaintiff deadlines announced; affected investors encouraged to seek legal representation.

Shareholder lawsuits target Kyndryl and uniQure with lead plaintiff deadlines approaching April 2026. Investors must act quickly to join litigation.

BioXcel Therapeutics settles $9.75M class action over securities purchased March-June 2023. Fairness hearing scheduled September 2026.

Federal court certifies class action against Biogen for alleged 2021 securities misrepresentations, affecting purchasers during June-July period.

Shareholder lawsuits against Nektar Therapeutics ($NKTR) and Eos Energy ($EOSE) allege clinical trial and production capacity disclosure failures, with lead plaintiff deadlines in April-May 2026.

Shareholder lawsuits target $KD and $QURE over alleged disclosure violations, with lead plaintiff applications due April 13, 2026. Affected investors may pursue recovery.

Monteverde & Associates investigates four mergers including $TALK's $5.25/share sale to UHS, plus deals involving $ALIS, $JTAI, and $RLYB.

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.

Class action lawsuits filed against Paysafe and Oracle alleging material disclosure failures. Paysafe stock fell 27.6% on undisclosed risks; Oracle faces allegations over understated AI CapEx requirements.

Class action lawsuit filed against Picard Medical for fraudulent stock promotion scheme. Stock crashed 70% to $2.00/share. Investor deadline April 3, 2026.

Class action lawsuit filed against Ardent Health for allegedly inflating receivables. Stock plunged 34% after $43M revenue decrease revealed in Q3 2025.

Pomerantz LLP investigates potential investor claims against Aardvark Therapeutics and FS KKR Capital Corp, while retracting prior Ambarella notice.

Federal court approves $1.6M class action settlement for Cummins investors. Settlement fairness hearing scheduled May 2026; claim deadline April 23, 2026.

Law firm investigates whether European Wax Center's $5.80/share buyout offer adequately values shareholders, citing analyst price targets over 150% higher.

Kaskela Law investigates whether Clearwater Analytics' $24.55/share buyout offer is fair, noting analysts target $35+, implying 43% potential undervaluation.

Kaskela Law LLC investigates KORE Group's $9.25 per share acquisition by Searchlight Capital and Abry Partners, questioning transaction fairness and potential fiduciary breaches.